التفاصيل البيبلوغرافية
| العنوان: |
TREATMENT FOR DARK ADAPTATION |
| Document Number: |
20100047330 |
| تاريخ النشر: |
February 25, 2010 |
| Appl. No: |
12/245944 |
| Application Filed: |
October 06, 2008 |
| مستخلص: |
The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide. |
| Inventors: |
Schwartz, Daniel M. (San Francisco, CA, US); Duncan, Keith G. (San Francisco, CA, US); Bailey, Kathy R. (San Francisco, CA, US); Kane, John P. (Hillsborough, CA, US); Ishida, Brian Y. (Walnut Creek, CA, US) |
| Claim: |
1. A method of treating macular degeneration in an individual, comprising the step of increasing reverse cholesterol transport in an ocular tissue of the individual, wherein said increasing reverse cholesterol transport comprises increasing Apolipoprotein A-I (ApoA-I) level in the ocular tissue. |
| Claim: |
2. The method of claim 1, wherein said increasing ApoA-I level comprises administering to the individual a therapeutically effective amount of an ApoA-I composition. |
| Claim: |
3. The method of claim 2, wherein the ApoA-I composition comprises an ApoA-I polypeptide or peptide. |
| Claim: |
4. The method of claim 3, wherein the ApoA-I peptide comprises SEQ ID NO:15. |
| Claim: |
5. The method of claim 3, wherein the ApoA-I peptide comprises SEQ ID NO:16. |
| Claim: |
6. The method of claim 3, wherein the ApoA-I polypeptide or peptide comprises D-amino acids. |
| Claim: |
7. The method of claim 1, wherein increasing the ApoA-I level comprises upregulating expression of ApoA-I. |
| Claim: |
8. The method of claim 1, wherein increasing the ApoA-I level is further defined as administering an agent to the individual, such that said agent increases the level of circulating ApoA-I in the individual. |
| Claim: |
9. The method of claim 8, wherein the agent comprises 1,2 dimyristoyl-α-glycero-3-phosphocholine (DMPC). |
| Claim: |
10. The method of claim 1, wherein the composition is administered to the individual locally or systemically. |
| Claim: |
11. The method of claim 1, wherein the composition is administered orally, parenterally, topically, intradermally, subcutaneously, intramuscularly, intraperitoneally, or intravenously. |
| Claim: |
12. The method of claim 6, wherein said composition is administered to an individual orally, wherein said composition is further defined as comprising a liposome. |
| Claim: |
13. A method of increasing lipid efflux from an ocular tissue comprising the step of increasing the level of ApoA-I in said tissue. |
| Claim: |
14. A method of treating macular degeneration (AMD) in an individual, comprising the step of delivering a therapeutically effective amount of a liposome comprising ApoA-I to at least one tissue of the individual. |
| Current U.S. Class: |
424/450 |
| Current International Class: |
61; 61; 61 |
| رقم الانضمام: |
edspap.20100047330 |
| قاعدة البيانات: |
USPTO Patent Applications |
